A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

NCT02337387 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

28

Enrollment

INDUSTRY

Sponsor class

Stopped Protocol stopping criteria (safety) were met.

Conditions

Osteoporosis, Postmenopausal

Interventions

BIOLOGICAL: Blosozumab
OTHER: Placebo

Sponsor

Eli Lilly and Company